ARS Pharmaceuticals, Inc.: income tax expense or benefit
Income tax expense or benefit for ARS Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ARS Pharmaceuticals, Inc. financial histories
What this measure means
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
Exact concept: us-gaap:IncomeTaxExpenseBenefit. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -80,000 | USD | 2026-03-09 | 10-K · 0001193125-26-097478 |
| 2024-01-01 | 2024-12-31 | 288,000 | USD | 2026-03-09 | 10-K · 0001193125-26-097478 |
| 2023-01-01 | 2023-12-31 | 0 | USD | 2025-03-20 | 10-K · 0000950170-25-042320 |
| 2022-01-01 | 2022-12-31 | 0 | USD | 2024-03-21 | 10-K · 0000950170-24-034689 |
| 2021-01-01 | 2021-12-31 | 0 | USD | 2023-03-23 | 10-K · 0000950170-23-009491 |
| 2020-01-01 | 2020-12-31 | 0 | USD | 2022-03-31 | 10-K · 0000950170-22-005202 |
Related financial histories
- ARS Pharmaceuticals, Inc.: total assets
- ARS Pharmaceuticals, Inc.: total liabilities
- ARS Pharmaceuticals, Inc.: stockholders equity
- ARS Pharmaceuticals, Inc.: cash and cash equivalents
- ARS Pharmaceuticals, Inc.: net income or loss
- ARS Pharmaceuticals, Inc.: operating cash flow
- ARS Pharmaceuticals, Inc.: capital expenditure payments
- ARS Pharmaceuticals, Inc.: contract revenue excluding tax
- ARS Pharmaceuticals, Inc.: financing cash flow
- ARS Pharmaceuticals, Inc.: investing cash flow
- ARS Pharmaceuticals, Inc.: retained earnings or deficit
- ARS Pharmaceuticals, Inc.: basic weighted-average shares
- ARS Pharmaceuticals, Inc.: diluted weighted-average shares
- ARS Pharmaceuticals, Inc.: basic earnings per share
- ARS Pharmaceuticals, Inc.: diluted earnings per share
- ARS Pharmaceuticals, Inc.: net property, plant and equipment
- ARS Pharmaceuticals, Inc.: share-based compensation expense
- ARS Pharmaceuticals, Inc.: operating income or loss
- ARS Pharmaceuticals, Inc.: current assets
- ARS Pharmaceuticals, Inc.: current liabilities
- ARS Pharmaceuticals, Inc.: current accounts payable
- ARS Pharmaceuticals, Inc.: net current accounts receivable
- ARS Pharmaceuticals, Inc.: operating expenses
- ARS Pharmaceuticals, Inc.: net inventory
- ARS Pharmaceuticals, Inc.: selling, general and administrative expense
- ARS Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- ARS Pharmaceuticals, Inc. / CIK 0001671858
- Captured
- 2026-09-21T17:22:41.931Z
- SEC response SHA-256
2c5a7142d269b28831cca7ac1261f0995af95a67f581ad2648504d2117d943c8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001671858.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))